Verrica Pharmaceuticals (FRA:1NE) 5-Year EBITDA Growth Rate : 6.90% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals 5-Year EBITDA Growth Rate?

Verrica Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-0.35.

During the past 3 years, the average EBITDA Per Share Growth Rate was 4.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Verrica Pharmaceuticals was 17.40% per year. The lowest was -127.00% per year. And the median was 4.50% per year.

Competitive Comparison of Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.

Verrica Pharmaceuticals 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Verrica Pharmaceuticals (FRA:1NE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Verrica Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (FRA:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

VRCA:USA 1NE:Germany

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines